Evidence map›Paper›PMID 36065182›Full record

ArticleiScience2022

Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease.

Partho Sen, Olivier Govaere, Tim Sinioja, Aidan McGlinchey, Dawei Geng, Vlad Ratziu, Elisabetta Bugianesi, Jörn M Schattenberg, Antonio Vidal-Puig, Michael Allison and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Lipid metabolism in MASLD and MASH: From mechanism to the clinic.JHEP reports : innovation in hepatology · 2024
    Review
  7. Article
  8. Review
  9. Hepatic glucose metabolism in the steatotic liver.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 6 countries.

Partho SenSchool of Medical Sciences, Örebro University, 70281 Örebro, Sweden.
Olivier GovaereTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Tim SiniojaDepartment of Chemistry, Örebro University, 70281 Örebro, Sweden.
Aidan McGlincheySchool of Medical Sciences, Örebro University, 70281 Örebro, Sweden.
Dawei GengDepartment of Chemistry, Örebro University, 70281 Örebro, Sweden.
Vlad RatziuAssistance Publique-Hôpitaux de Paris, hôpital Beaujon, University Paris-Diderot, Paris, France.
Elisabetta BugianesiDepartment of Medical Sciences, Division of Gastro-Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
Jörn M SchattenbergMetabolic Liver Research Programm, Department of Medicine, University Hospital Mainz, Mainz, Germany.
Antonio Vidal-PuigUniversity of Cambridge Metabolic Research Laboratories, Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Michael AllisonLiver Unit, Department of Medicine, Cambridge Biomedical Research Centre, Cambridge University NHS Foundation Trust, UK.
Simon CockellTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Ann K DalyTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Tuulia HyötyläinenDepartment of Chemistry, Örebro University, 70281 Örebro, Sweden.
Quentin M AnsteeTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Matej OrešičSchool of Medical Sciences, Örebro University, 70281 Örebro, Sweden.
Örebro University · SENewcastle University · GBÅbo Akademi University · FICambridge University Hospitals NHS Foundation Trust · GBDélégation Paris 7 · FRJohannes Gutenberg University Mainz · DENewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBUniversity of Turin · IT

Funding

British Heart Foundation RG/18/7/33636Medical Research Council G0400192Medical Research Council G0802051Medical Research Council MC_UU_00014/2Medical Research Council MC_UU_00014/5Medical Research Council MC_UU_12012/2
6 · The paper itself

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent disease that is associated with multiple metabolic disturbances, yet the metabolic pathways underlying its progression are poorly understood. Here, we studied metabolic pathways of the human liver across the full histological spectrum of NAFLD. We analyzed whole liver tissue transcriptomics and serum metabolomics data obtained from a large, prospectively enrolled cohort of 206 histologically characterized patients derived from the European NAFLD Registry and developed genome-scale metabolic models (GEMs) of human hepatocytes at different stages of NAFLD. We identified several metabolic signatures in the liver and blood of these patients, specifically highlighting the alteration of vitamins (A, E) and glycosphingolipids, and their link with complex glycosaminoglycans in advanced fibrosis. Furthermore, we derived GEMs and identified metabolic signatures of three common NAFLD-associated gene variants

Indexed as

Health sciencesMetabolomicsOmicsSystems biology

Identifiers

PMID36065182
PMCPMC9440293
OpenAlexW4291790793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.